Sands Capital, an active and long-term investor in leading innovative businesses, announced the closing of its third life sciences fund, Sands Capital Life Sciences Pulse Fund III (Pulse III), at $555 million. Pulse III was met with high demand from existing and new limited partners.
This closing increases total Pulse strategy capital commitments to $1.3 billion, including Sands Capital Life Sciences Pulse Fund (Pulse I) and Sands Capital Life Sciences Pulse Fund II (Pulse II).
The team will be continuing to invest with the same emphasis on private therapeutics, diagnostics, medical devices, and life sciences tools businesses, in support of the strategy’s mission to help transform how diseases are defined, diagnosed, and treated.
Pulse’s investment team comprises senior professionals led by founders, operators, PhDs, and experienced investors with the ability to leverage the resources and capabilities of the entire firm to execute its strategy. And the team also draws upon Sands Capital’s 3+ decades of deep research and experience investing in innovation in public markets.
As of March 31, 2024, Sands Capital managed $54+ billion in public and private equity investments, including $5+ billion in life sciences and healthcare companies globally across all strategies.
KEY QUOTE:
“The life sciences sector continues to innovate at a rapid pace, leading to breakthroughs that benefit both patients and society as a whole. We are grateful to both the investors joining us in Pulse III and the talented management teams we’ve partnered with since the strategy’s inception.”
– Stephen Zachary, Managing Partner
